Amgen (AMGN) vs BioNTech (BNTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Amgen (AMGN) has outperformed BioNTech (BNTX) over the past year, gaining 39.8% versus a loss of 10.2%. Over five years, AMGN leads with a +98.7% price change compared with -61.5% for BNTX. Amgen is the larger company by market cap ($217.65 billion vs $23.25 billion), about 9.4 times the size.
Amgen pays a dividend yielding 2.43%, while BioNTech does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMGN | BNTX |
|---|---|---|
| Share price | $402.59 | $92.55 |
| Market cap | $217.65B | $23.25B |
| 1-day change | -2.54% | -2.83% |
| YTD return | +26.20% | +0.05% |
| 1-year return | +39.77% | -10.19% |
| 5-year return | +98.75% | -61.54% |
| P/E ratio (TTM) | 25.01 | — |
| Forward P/E | 16.45 | — |
| EPS (TTM) | $16.10 | $-7.83 |
| Dividend yield | 2.43% | 0.00% |
| Annual dividend | $9.80 | $0.00 |
| Revenue (latest FY) | $36.75B | — |
| Revenue growth (YoY) | +9.95% | — |
| Net income (latest FY) | $7.71B | — |
| Gross margin | 67.25% | — |
| Operating margin | 24.71% | — |
| Net margin | 20.98% | — |
| 52-week high | $447.03 | $124.00 |
| 52-week low | $288.00 | $79.52 |
| Distance from 52-week high | -9.94% | -25.36% |
| Analyst consensus | hold | buy |
| Avg. price target upside | -2.76% | +25.11% |
| Average volume | 2.73M | 1.15M |
| Shares outstanding | 540.63M | 251.20M |
| Employees | 31,500 | 7,807 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Amgen is about 9.4 times larger than BioNTech by market value ($217.65B vs $23.25B).
- AMGN has outperformed BNTX by 50.0 percentage points over the past year.
- Amgen offers a meaningfully higher dividend yield (2.43% vs 0.00%).
About Amgen
AMGN stock →Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 31,500 employees
About BioNTech
BNTX stock →BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,807 employees
AMGN vs BNTX FAQ
Which is bigger, Amgen or BioNTech?
Amgen (AMGN) is larger, with a market capitalization of $217.65B compared with $23.25B for BioNTech (BNTX).
Which stock has performed better over the past year, AMGN or BNTX?
AMGN returned +39.77% over the past 12 months, compared with -10.19% for BNTX (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Amgen or BioNTech?
Amgen pays a dividend yielding 2.43%, while BioNTech does not currently pay a regular dividend.
Are Amgen and BioNTech in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.